Skip to content
10-Q

Quarterly Report

Cogent Biosciences, Inc. COGT

0000950170-25-064005

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 113.86M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $126M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $98.17M
Current Liabilities Q1 2025 · Mar 31, 2025 $49.32M
Current Liabilities Q1 2025 · Dec 31, 2024 $55.71M
Total Liabilities Q1 2025 · Mar 31, 2025 $64.8M
Total Liabilities Q1 2025 · Dec 31, 2024 $71.61M
Current Assets Q1 2025 · Mar 31, 2025 $252.88M
Current Assets Q1 2025 · Dec 31, 2024 $296.47M
Total Assets Q1 2025 · Mar 31, 2025 $283.8M
Total Assets Q1 2025 · Dec 31, 2024 $327.9M
Shares Diluted Q1 2025 · Mar 31, 2024 94.8M sh
Capex Q1 2025 · Mar 31, 2024 $70K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$52.53M
Stockholders Equity Q1 2025 · Mar 31, 2024 $422.33M
Stockholders Equity Q1 2025 · Dec 31, 2023 $257.8M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.49
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.49
Sga Expense Q1 2025 · Mar 31, 2024 $9.7M
Rd Expense Q1 2025 · Mar 31, 2024 $52.71M
Net Income Q1 2025 · Mar 31, 2024 −$58.35M
Operating Income Q1 2025 · Mar 31, 2024 −$62.4M